Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the month of April 2023, specifically dated April 13, 2023. The Company, a foreign private issuer headquartered in Jena, Germany, reports the execution of an Underwriting Agreement dated April 11, 2023, with Raymond James & Associates, Inc. as the representative underwriter.
Key Financial Metrics
The filing details a public offering of ordinary shares rather than reporting operational financial results such as revenue or profit.
- Shares Offered: 9,411,765 ordinary shares at a public offering price of $4.25 per share.
- Over-Allotment Option: Underwriters hold a 30-day option to purchase up to an additional 1,411,764 shares.
- Estimated Gross Proceeds: Approximately $40 million from the base offering, or approximately $46 million if the over-allotment option is exercised in full.
- Net Proceeds: The filing states gross proceeds are before deducting underwriting discounts and estimated offering expenses; specific net amounts are not provided.
- Debt and Liquidity: The filing text does not provide clear values for current debt levels, cash flow, or liquidity metrics outside of the anticipated proceeds from this offering.
Material Changes
The primary material change reported is the initiation of a capital raise via a public offering. This represents a significant increase in the Company's share count and anticipated cash resources compared to the prior period, subject to the closing of the transaction.
Guidance, Outlook, and Risks
Outlook and Closing: The Offering is expected to close on or about April 14, 2023, subject to customary closing conditions. The transaction is made pursuant to an effective shelf registration statement on Form F-3.
Risks and Contingencies: The Underwriting Agreement includes customary representations, warranties, and indemnification provisions where the Company agrees to indemnify Underwriters against certain liabilities under the Securities Act of 1933. The filing does not provide specific management commentary on future operational guidance or clinical trial timelines.
Investor Verification Checklist
- Verify the final closing date of the Offering, as it is currently expected "on or about April 14, 2023."
- Confirm whether the Underwriters exercise the 30-day option to purchase the additional 1,411,764 shares.
- Review the final prospectus supplement to determine the exact underwriting discount and offering expenses to calculate net proceeds.
- Check subsequent filings for the updated share count and capitalization table post-closing.